India, March 11 -- Achieve Life Sciences, Inc. (ACHV), a late-stage specialty pharmaceutical company, Tuesday reported net loss of $12.36 million or $0.36 per share, higher than $5.48 million or $0.26 per share loss in the same quarter a year.
As of December 31, 2024, the company's cash, cash equivalents, and marketable securities was $34.4 million.
The company also confirmed its plan to submit new drug application (NDA) for cytisinicline for the treatment of nicotine dependence, at the end of the second quarter of 2025.
For comments and feedback contact: editorial@rttnews.com
Published by HT Digital Content Services with permission from RTT News....